drugset / Trial / NCT06104449
A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy and safety of opevesostat in the treatment of Japanese men with metastatic castration-resistant prostate cancer (mCRPC) previously treated with Next Generation Hormonal Agent (NHA) and taxane-based chemotherapy.
Timeline
- Start
- 2023-11-14
- Primary completion
- 2026-02-20
- Completion
- 2026-04-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Opevesostat | Small molecule | 5 mg | Oral |
| Background | Dexamethasone | Small molecule | 1.5 mg | Oral |
| Background | Fludrocortisone | Other / unclassified | 0.1 mg | Oral |
| Background | Hydrocortisone | Other / unclassified | 100 mg | Oral |